Daiichi Sankyo, Lilly Submit New Drug Application For Investigational Antiplatelet Drug, Prasugrel, With U.S. Food And Drug Administration
Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA). Prasugrel is an oral antiplatelet agent, initially in development for the treatment of patients with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention (PCI), including coronary stenting.
More: continued here
Filed under: Cardiovascular on January 5th, 2008